At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
rozanolixizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2A, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
In Brief
A Phase 2 clinical trial evaluating rozanolixizumab and Placebo for Fibromyalgia. Completed, enrolled 63 participants across 7 sites.
Detailed Summary
The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartDec 2022
Primary CompletionMay 2024
Study CompletionJul 2024
TodayJul 2026
First PostedDec 9, 2022
Enrollment StartDec 21, 2022
Primary CompletionMay 28, 2024
Study CompletionJul 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.6 years ago
Interventions
rozanolixizumabdrug
Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
Placeboother
Study participants will receive Placebo during the dosing periods as pre-defined.